eosinophilic chronic rhinosinusitis with nasal polyps
Conditions
Interventions
Gold Standard:The gold standard for confirming the diagnosis of eosinophilic chronic sinusitis with nasal polyps is to obtain tissue by biopsy and then confirm the classification by pathological secti
Index test:Real-time Typing Diagnosis System for Eosinophilic Nasal Polyps Based on High-sensitivity Spectroscopy Technology and Autofluorescence Recognition Technology
Sponsors
The Affiliated Hospital of Qingdao University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Male and female subjects aged 18-65 years; 2. Subjects were diagnosed with CRSwNP by nasal endoscopy, CT or MRI before surgery (meeting EPOS 2020 diagnostic criteria); 3. Normal coagulation function (PT, APTT, platelet count within normal range); 4. No severe cardiopulmonary dysfunction or other comorbidities affecting general anesthesia and surgical tolerance; 5. Women of childbearing age must take adequate medical contraception during the study period and within 4 weeks after the end of trial treatment; 6. Patients have good compliance, voluntarily participate in this clinical study and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1.Patients with other nasal and paranasal sinus diseases excluding chronic rhinosinusitis (such as nasal tumors, fungal sinusitis, and post-traumatic nasal deformities); 2.Patients with coagulation dysfunction, immunodeficiency, or long-term use of anticoagulant/antiplatelet drugs at the time of visit, and females during menstruation; 3.Patients who have taken oral glucocorticoids within 1 month prior to the visit; 4.Patients with a history of nasal endoscopic surgery or nasal radiotherapy; 5.Pregnant or lactating women, or those with severe systemic diseases (such as uncontrolled hypertension, diabetes, hepatic or renal insufficiency); 6.Patients with incomplete clinical data or missing postoperative follow-up data; 7.Any other conditions deemed by the researcher as making the subject unsuitable for participating in the trial; 8.Patients with poor treatment compliance.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The agreement between the results of device-based typing diagnosis and the pathological gold standard; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence rate of operation-related adverse events associated with spectral equipment; | — |
Countries
China
Contacts
Public ContactYan Jiang
The Affiliated Hospital of Qingdao University
Outcome results
None listed